Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06564142 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv37
  2. Primary and study completion dates: Sep 30, 2028 to Jan 30, 2028 Secondary endpoints: 3 to 4v36 Show 1 more changeShow less
    • Secondary endpoints: 3 to 4

    See this version in full on ClinicalTrials.gov ↗

  3. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 480 to confirmed 605 · Study description shortened, about 15 words · Site details revised at 318 of 318 sitesv35 Show 3 more changesShow less
    • Enrollment target: estimated 480 to confirmed 605
    • Study description shortened, about 15 words
    • Site details revised at 318 of 318 sites

    See this version in full on ClinicalTrials.gov ↗

  4. Study description expanded, about 15 words Site details revised at 1 of 318 sitesv34 Show 1 more changeShow less
    • Site details revised at 1 of 318 sites

    See this version in full on ClinicalTrials.gov ↗

  5. Study sites: 317 to 318v33
Show 31 earlier versionsHide 31 earlier versions
  1. Study sites: 307 to 317v32
  2. Study sites: 304 to 307v31
  3. Study sites: 301 to 304v30
  4. Study sites: 297 to 301v29
  5. Study sites: 296 to 297v28
  6. Study sites: 295 to 296v27
  7. Study sites: 294 to 295v26
  8. Study sites: 292 to 294v25
  9. Study sites: 276 to 292v24
  10. Study sites: 270 to 276v23
  11. Study sites: 257 to 270v22
  12. Study sites: 253 to 257v21
  13. Study sites: 246 to 253v20
  14. Study sites: 242 to 246v19
  15. Study sites: 233 to 242v18
  16. Study sites: 225 to 233v17
  17. Study sites: 222 to 225v16
  18. Study sites: 212 to 222v15
  19. Study sites: 193 to 212v14
  20. Study sites: 185 to 193v13
  21. Study sites: 56 to 185 Primary and study completion dates: Sep 2028 to Sep 30, 2028v12 Show 1 more changeShow less
    • Primary and study completion dates: Sep 2028 to Sep 30, 2028
  22. Study sites: 49 to 56v11
  23. Eligibility criteria shortened, about 5 wordsv10 See this version in full on ClinicalTrials.gov ↗
  24. Study sites: 31 to 49v9
  25. Study sites: 28 to 31v8
  26. Study sites: 25 to 28v7
  27. Study sites: 22 to 25v6
  28. Study sites: 18 to 22 Eligibility criteria revisedv5 Show 1 more changeShow less
    • Eligibility criteria revised

    See this version in full on ClinicalTrials.gov ↗

  29. Study sites: 13 to 18v4
  30. Study sites: 12 to 13v3
  31. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 12 · Start date changed from estimate of Aug 2024 to Aug 30, 2024v2 Show 2 more changesShow less
    • Study sites: 0 to 12
    • Start date changed from estimate of Aug 2024 to Aug 30, 2024
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the efficacy of povetacicept in adult participants compared with placebo in reducing proteinuria and preserving renal function.
Trial Details
NCT Number NCT06564142
Lead Sponsor Alpine Immune Sciences Inc, A Subsidiary of Vertex
Conditions Immunoglobulin A Nephropathy
Enrollment 605 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov